Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Mitochondria are the energy-producing factories inside cells. Sometimes genetic mutations can cause these factories to go wrong, leading to a number of neurological diseases. The same genetic mutation affecting mitochondrial function can result in a specific deficit such as loss of vision or a more complicated disorder such as Parkinson’s-like disease.  It is not yet known why the same mutation can have such varying effects.

One gene that behaves in this fashion when mutated is OPA1. Mutations of this gene are the commonest cause of dominantly inherited optic atrophy, but in 25% of affected individuals, they cause more diverse neurological symptoms including parkinsonism. Researchers at NDCN led by Dr Tofaris worked with patients experiencing optic atrophy with or without Parkinson’s symptoms due to loss of OPA1 function. They sequenced all their gene-coding regions and generated stem cell-derived neurons. The results, published in the Annals of Neurology, suggest that the genetic makeup of individuals with loss of OPA1 function may determine whether they develop Parkinson’s symptoms, by worsening the underlying mitochondrial defect. 

The researchers showed how the loss of OPA1 function affects the ability of stem cell-derived neurons to generate energy as they age in culture in the lab. A defect in the mechanism that holds mitochondria linked together as networks, called OPA1-mediated fusion, is associated with cell death in the dish and clinical severity in patients. This is important because it suggests that targeting OPA1-mediated fusion in common diseases where mitochondria are especially important, such as Parkinson’s, could be a route to developing therapies to counteract neurodegeneration.

More broadly, the study demonstrates how this kind of deep-phenotyping of a rare disease using stem cell modelling can help contextualise key functions of essential mitochondrial proteins in the study of disease severity. It suggests that mapping the effect of individuals’ genetic makeup in mitochondrial diseases could have prognostic value.

Similar stories

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Royal Academy of Engineering Research Fellowship

Dr Rezvan Farahibozorg has received one of 17 Royal Academy of Engineering Research Fellowships for 2022.

Three New Professors

Many congratulations to the following members of our Department who have been awarded the title of Professor in the recent Recognition of Distinction round.

Repurposed drug could help patients with motor neuron disease

A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND), according to a new study.

Finding out more about Parkinson’s by monitoring symptoms at home

Professor Chrystalina Antoniades explains how the COVID pandemic accelerated an innovation in one research project into Parkinson's Disease.